Group items tagged

Colonis, a subsidiary company of the Clinigen Group has received the Medicines and Healthcare products Regulatory Agency (MHRA) approval for Melatonin 1mg/ml Oral Solution for sleep onset insomnia in children and adolescents aged 6-17 years with attention-deficit hyperactivity disorder (ADHD). Clinical evidence demonstrates that Melatonin has the potential to decrease sleep latency and increase sleep efficiency in children with ADHD and chronic sleep onset insomnia. Children with ADHD are statistically more likely to have sleep onset insomnia than non-ADHD children. The prevalence of sleep onset insomnia in children with ADHD ranges from 25%-50%. Sleep onset insomnia in children with ADHD can affect their mood, attention, behaviour and school performance. Henno Welgemoed, Director of Medical Affairs at Colonis said: "We welcome the MHRA's approval for a condition that negatively affects the quality of life for children and adolescents diagnosed with ADHD and increases the burden for support networks."

The NHS has started using a new digital test to accelerate the diagnosis of attention-deficit hyperactivity disorder (ADHD) in children, following successful trials by the National Institute for Health and Care Research (NIHR). In July 2024, the National Institute for Health and Care Excellence (NICE) issued draft guidance approving the use of QbTest by psychiatrists and specialist children's doctors to aid in ADHD diagnoses. This computerised test, which complements existing diagnostic methods, is expected to both improve assessment accuracy and save the NHS money. It is estimated that ADHD affects 3-5 per cent of school-age children, who show symptoms of inattention, impulsivity and hyperactivity. Professor Richard Morriss, NIHR ARC East Midlands Mental Health and Well-being Theme Lead, expressed concern that there has been a fourfold increase in ADHD referrals since the COVID-19 pandemic.

The recent data released by the NHS England revealed that in 2022/23 nearly 86 million antidepressant items were prescribed to around 8.6 million identified patients. According to the statistic published on 'Medicines Used in Mental Health' of the 5 British National Formulary (BNF) sections, 4 had increases in items and identified patients across 2022/23. The only BNF section to decrease since 2021/22 was hypnotics and anxiolytics. Items fell by 2% to 14 million and identified patients fell by 2 per cent to 1.9 million in 2022/23 The data also revealed that Prescribing of Central Nervous System (CNS) stimulants and drugs for ADHD increased by 32 per cent in adults over 18 and 12 per cent in children 17 and under. "2022/23 was the first time that more adult patients have been prescribed drugs from this section than child patients, in the time period covered by these statistics," said the report.